<?xml version='1.0' encoding='utf-8'?>
<document id="24898293"><sentence text="Facile LC-UV methods for simultaneous monitoring of ciprofloxacin and rosuvastatin in API, formulations and human serum."><entity charOffset="52-65" id="DDI-PubMed.24898293.s1.e0" text="ciprofloxacin" /><entity charOffset="70-82" id="DDI-PubMed.24898293.s1.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24898293.s1.e0" e2="DDI-PubMed.24898293.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24898293.s1.e0" e2="DDI-PubMed.24898293.s1.e1" /></sentence><sentence text="An efficient, selective and cost-effective liquid chromatographic assay was developed and validated for the simultaneous quantification of ciprofloxacin and rosuvastatin in Active Pharmaceutical Ingredients (API), pharmaceutical formulations and in human serum"><entity charOffset="139-152" id="DDI-PubMed.24898293.s2.e0" text="ciprofloxacin" /><entity charOffset="157-169" id="DDI-PubMed.24898293.s2.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24898293.s2.e0" e2="DDI-PubMed.24898293.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24898293.s2.e0" e2="DDI-PubMed.24898293.s2.e1" /></sentence><sentence text=" The chromatographic system consisted of mobile phase methanol-water, 90:10 v/v at pH 3"><entity charOffset="54-62" id="DDI-PubMed.24898293.s3.e0" text="methanol" /></sentence><sentence text="0 adjusted with o-phosphoric acid, pumped at 1"><entity charOffset="16-33" id="DDI-PubMed.24898293.s4.e0" text="o-phosphoric acid" /></sentence><sentence text="0 mL/min through a prepacked Purospher Star C18 (5 µm, 25 × 0" /><sentence text="46 cm) column and effluent was monitored at the isosbestic point (255 nm) as well as at the λmax of individual drugs (243 and 271 nm)" /><sentence text=" The method was validated over a linear concentration range of 0" /><sentence text="25-15 µg/mL for ciprofloxacin and 0"><entity charOffset="16-29" id="DDI-PubMed.24898293.s8.e0" text="ciprofloxacin" /></sentence><sentence text="33-20 µg/mL for rosuvastatin (r(2)  ≥ 0"><entity charOffset="16-28" id="DDI-PubMed.24898293.s9.e0" text="rosuvastatin" /></sentence><sentence text="999)" /><sentence text=" The ranges of reliable response (limits of detection and quantitation) for ciprofloxacin were 3-15 and 9-45 ng/mL and 17-29 and 52-88 ng/mL, respectively, for rosuvastatin in all API, pharmaceutical formulations and human serum"><entity charOffset="76-89" id="DDI-PubMed.24898293.s11.e0" text="ciprofloxacin" /><entity charOffset="160-172" id="DDI-PubMed.24898293.s11.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24898293.s11.e0" e2="DDI-PubMed.24898293.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24898293.s11.e0" e2="DDI-PubMed.24898293.s11.e1" /></sentence><sentence text=" Analytical recovery from human serum was &gt;98% and relative standard deviation (RSD) was &lt;2" /><sentence text=" The accuracies were 97" /><sentence text="13-102" /><sentence text="55 and 97" /><sentence text="41-101" /><sentence text="31% and precisions in RSD were 0" /><sentence text="04-1" /><sentence text="90 and 0" /><sentence text="02-1" /><sentence text="23% for ciprofloxacin and rosuvastatin, respectively"><entity charOffset="8-21" id="DDI-PubMed.24898293.s21.e0" text="ciprofloxacin" /><entity charOffset="26-38" id="DDI-PubMed.24898293.s21.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24898293.s21.e0" e2="DDI-PubMed.24898293.s21.e0" /><pair ddi="false" e1="DDI-PubMed.24898293.s21.e0" e2="DDI-PubMed.24898293.s21.e1" /></sentence><sentence text=" No matrix interferences, ion suppression/enhancement and carry-over were detected" /><sentence text=" The total assay run time was less than 5 min" /><sentence text=" In another study, for optimum performance the detector was programmed for multiwavelength scanning at the absorption maxima of each component" /><sentence text=" Consequently, the linearity range was improved and limit of detection and quantitation values were down to 1-4 and 4-12 ng/mL for ciprofloxacin and 3-5 and 9-15 ng/mL for rosuvastatin, respectively"><entity charOffset="131-144" id="DDI-PubMed.24898293.s25.e0" text="ciprofloxacin" /><entity charOffset="172-184" id="DDI-PubMed.24898293.s25.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24898293.s25.e0" e2="DDI-PubMed.24898293.s25.e0" /><pair ddi="false" e1="DDI-PubMed.24898293.s25.e0" e2="DDI-PubMed.24898293.s25.e1" /></sentence><sentence text=" The validation parameters fitted ICH guidelines through the isosbestic and individual λmax approach" /><sentence text=" The small sample volume and simplicity of preparation make this method suitable for use in human serum samples, pharmaceutical formulations, quality control, drug-drug interaction studies, clinical laboratories, drug research centers and forensic medical centers" /><sentence text="" /></document>